CHICAGO (Reuters) – As the first federal jury deliberates whether Merck & Co.’s painkiller Vioxx contributed to a Florida man’s death, investors on Friday digested new claims that the battered company withheld key data about the drug’s dangers.

Merck’s shares fell nearly 2 percent to $29.1 1 in New York Stock Exchange trading after the prestigious New England Journal of Medicine on Thursday claimed Merck deleted information about three heart attacks from a Key Vioxx study submitted for publication.

Merck said it disclosed the events to U.S. regulators in 2000 and publicly in 2001, including in several press releases.

While analysts said the events do not change conclusions of the study, which showed Vioxx carried a higher risk of heart attack than a common painkiller, the negative headlines represent another blow for the stock and are likely to be used as fodder in future cases against Merck.

Citigroup analyst George Grofik, in a research note, said it’s not yet clear whether the federal jury deliberating in Huston has seen news reports of the journal’s allegations.

“While the data is not new, clearly this editorial puts a spotlight on Merck’s conduct and potentially provides plaintiff attorneys with additional fodder,” said Grofik, who maintained his “hold” rating on the stock.

According to the Wall Street Journal, plaintiffs in the trial filed a motion seeking a mistrial, citing the missing data from the study.

The paper reported the judge in the case, Eldon Fallon, said he will take the plaintiffs’ motion under advisement.

Judge Fallon’s staff declined to comment to Reuters on whether a mistrial motion was filed, as did both plaintiff and Merck lawyers.

The clerk of the court could not confirm whether such a motion had been filed.

Bank of America analyst Chris Schott, in a research note, said, the negative publicity “clearly does not help Merck as it works to defend itself against Vioxx litigation.”



We're here to help!

We live by our creed of "helping those who need it most" and have helped thousands of clients get the justice they desperately needed and deserved. If you feel you have a case or just have questions please contact us for a free consultation. There is no risk and no fees unless we win for you.

Fields marked    may be required for submission.
  1. I'm an attorney

Merck to pay $830 million to settle investors’ Vioxx...

Merck announced Friday it will pay $830 million to settle investor complaints accusing it of committing...

Merck to pay nearly $1 billion for illegal marketing...

American pharmaceutical company Merck, Sharp & Dohme has agreed to pay $950 million to resolve criminal...

Merck paying more than 3,100 vioxx death claims

Merck & Co. is paying claims by the families of more than 3,100 users of its Vioxx painkiller who...

Settlement limits insurers' claims in Vioxx deal

TRENTON, N.J. (AP) -- Former Vioxx users getting part of a $4.85 billion settlement ending most personal...

Persistence pays in Vioxx litigation

Plaintiffs get close to $5B, but Merck could have done a lot worse. Attorneys who spent nearly one year...

Vioxx settlement payments to begin in August

Merck & Co., manufacturer of Vioxx, announced it will make the first payment of $500 million on Aug....

A special thanks

A special thanks to your law firm and staff for all the work done on the Vioxx case. The settlement could not have come at a better time for my family and myself. I thank you for a job well done!

—George